Patent 11052146 was granted and assigned to Novavax on July, 2021 by the United States Patent and Trademark Office.
The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.